37.91
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
How volatile is Revolution Medicines Inc. Equity Warrant stock compared to the marketUnlock expert stock analysis and alerts - jammulinksnews.com
How many analysts rate Revolution Medicines Inc. Equity Warrant as a “Buy”Triple returns potential - jammulinksnews.com
What catalysts could drive Revolution Medicines Inc. Equity Warrant stock higher in 2025Invest smarter with real-time trading signals - jammulinksnews.com
Is Revolution Medicines Inc. a growth stock or a value stockAchieve breakthrough investment performance - jammulinksnews.com
How strong is Revolution Medicines Inc. company’s balance sheetCapitalize on emerging market trends - jammulinksnews.com
What makes Revolution Medicines Inc. Equity Warrant stock price move sharplyFree Insider Trading Tips - Metal.it
What analysts say about Revolution Medicines Inc. stockSuperior stock selection - PrintWeekIndia
Revolution Medicines, Iambic Therapeutics Partner to Use AI for Novel RAS-Addicted Cancer Drug Discovery - Insider Monkey
What drives Revolution Medicines Inc. Equity Warrant stock priceTriple returns potential - Autocar Professional
What analysts say about Revolution Medicines Inc. Equity Warrant stockFastest-growing stock picks - PrintWeekIndia
Revolution Medicines publishes research on RAS G12D inhibitor - Investing.com
Revolution Medicines publishes research on RAS G12D inhibitor By Investing.com - Investing.com UK
Revolution Medicines Inc. Equity Warrant Stock Analysis and ForecastHigh-octane financial growth - Autocar Professional
What drives Revolution Medicines Inc. stock priceBreakthrough stock performance - Autocar Professional
Is Revolution Medicines Inc. a good long term investmentMarket-leading capital gains - Autocar Professional
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor - GlobeNewswire
RVMDRevolution Medicines, Inc. Latest Stock News & Market Updates - Stock Titan
Castle Biosciences, Revolution Medicines get FDA breakthrough statuses - MSN
Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs - MSN
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib - GlobeNewswire
Revolution Medicines Inc. Stock Analysis and ForecastConsistent wealth multiplication - jammulinksnews.com
FDA grants breakthrough therapy designation to Revolution Medicines’ lung cancer drug - Investing.com India
Revolution Medicines Secures FDA Breakthrough Status for Novel KRAS Lung Cancer Treatment - Stock Titan
How will RVMD's EPS trend in Q1 2025? - AInvest
Is Revolution Medicines Inc. Equity Warrant a good long term investmentConsistent high-performance stocks - jammulinksnews.com
자본화:
|
볼륨(24시간):